Treatments

*September 2021*      

*September 2021* Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer (NSCLC) harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial (NCT03318939) that were presented at the 2021 ESMO Congress.1…

*September 2021* Discussing the case for antibody drug conjugate (ADC) or tyrosine kinase inhibitor TKI for HER2 mutated lung cancer at ESMO 2021:⁦    

*September 2021* Dato-DXd is an ADC targeting TROP2 and delivering a potent topoisomerase I inhibitor. Efficacy seen in prior reports but this presentation focused on the subset of patients with NSCLC harboring an actionable driver alteration. (Dr. Stephen V. Liu)   Safety/Toxicity: Grade 3+ treatment emergent adverse events (TEAEs) seen in 38% of…

*September 2021* Encouraging preliminary findings from two ongoing studies of combination therapy with amivantamab plus the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib were presented today at the ESMO Congress 2021, offering novel promise to a patient population that has a high unmet need for new treatments, particularly in later-line…

*September 2021* DZD9008 is an orally bioavailable irreversible EGFR inhibitor being developed for EGFR and HER2 mutant NSCLC. This analysis is of the WU-KONG1 and WU-KONG2 trials and presented by Dr. Pasi Janne. Efficacy set included 56 patients (18 escalation, 38 expansion), all pretreated, 25 with prior EGFR TKI therapy, 7…

*September 2021* EGFR Resisters co-founder Ivy Elkins presented a mini-oral at WCLC 2021 about the real-world treatment trajectories of patients living with EGFR positive lung cancer. In this abstract, she states that although osimertinib is currently considered the standard of care for first-line treatment of patients with EGFR positive lung…

*September 2021* Dr. Pasi Jänne, MD, PhD, discusses promising studies from the meeting in this video. Transcript: A couple of them include the DESTINY-Lung trial, which was the trial of trastuzumab deruxtecan , a HER2 antibody drug conjugate in patients with HER2 mutant lung cancer. So this is a subset of…

*August 2021* Dr. Joel Neal discusses this topic with Dr. Neill Love. Listen to the entire podcast here. DR LOVE: So another agent we saw some Phase I data on was, patritumab deruxtecan, an anti-HER3 agent. What is it, and what did we learn about it at ASCO? DR NEAL: Yeah. So…